Profound Medical Reports Strong First Quarter 2026 Financial Results
Humana coverage and surging procedure volumes push TULSA-PRO toward standard of care, but path to profitability still requires execution.
The Q1 2026 earnings release (May 7, 2026) reports: - Revenue of ~$5.3 million, up 104% year‑over‑year (vs $2.6 million in Q1 2025). - Gross margin 72% (Q1 2025: 71%). - Operating expenses down 9% to ~$11.8 million; net loss improved to $7.0 million ($0.19/share) from $10.7 million. - Cash position $50.3 million as of March 31, 2026. - Installed base of 80 TULSA‑PRO systems; 6 systems shipped in the quarter. - Humana announced as the first national U.S. payer to cover the TULSA Procedure, adding ~8.5 million covered lives. - Same‑store procedure volumes (TULSA INDEX20) rose from 7.1 to 11.3 per quarter (59% YoY). - Full‑year 2026 revenue guidance set at ~$25 million (56% growth) with gross margin ≥70%. - CAPTAIN trial previously met primary safety endpoint (superior erectile function and continence preservation vs. robotic prostatectomy).
The most recent news represents a material positive development. Key factors: - Humana national coverage is a genuine surprise and arrives earlier than management’s timeline (previously guided “coverage decisions in H2 2026”). It instantly expands the reimbursed patient pool by ~8.5 million lives, directly supporting higher procedure volumes. - Revenue growth accelerating – triple‑digit YoY in Q1 and full‑year guide of 56% implies continued strong momentum, even after a very high prior‑year comparable. - Significant net loss improvement and gross margin stability (>70%) demonstrate operating leverage, with cash burn declining. - However, the stock price reaction on May 7 was muted (closed at $9.75, down slightly from prior day $9.89), suggesting the market partially anticipated the strong results. The real upside surprise is the payer breakthrough, validating the commercial model. - Contrast with the March 2025 sell‑off after FY2025 results (net loss of $42.6M) – the Q1 2026 update confirms that the financing and strategic moves are bearing fruit. - The news is not “game changer” in the sense of a takeover or first‑time investment by a legendary resource investor, but the Humana coverage is a meaningful catalyst for revenue acceleration and derisking of the reimbursement narrative.
Profound Medical is a commercial‑stage medical device company developing AI‑powered, MRI‑guided, incision‑free ablation platforms. Its flagship product, TULSA‑PRO, uses robotically controlled transurethral ultrasound with real‑time MR thermography to treat prostate cancer and benign prostatic hyperplasia (BPH). The procedure avoids blood loss, hospital stays, and reduces side‑effects like incontinence and erectile dysfunction. TULSA‑PRO is FDA 510(k) cleared, CE marked, and approved in multiple countries. The company also markets Sonalleve for uterine fibroids / adenomyosis and pain palliation, primarily outside the U.S.
Key clinical trial: CAPTAIN, a Level 1 randomized trial comparing TULSA to robotic radical prostatectomy. Safety endpoint met (March 2026); oncologic efficacy data pending late 2026.